The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Novel approach of prophylactic radiation to reduce toxicities comparing 2-step 40 Gy with 56 Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck: A phase III trial (JCOG1912, NEW BRIDGE).
 
Tomoya Yokota
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Lilly Japan; Merck; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Japan Agency for Medical Research and Development; Merck; MSD; Pharmaceuticals and Medical Devices Agency; Rakuten Medical
Research Funding - Abbvie (Inst); Ascent Pharmahealth (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Japan Agency for Medical Research and Development; Lilly Japan (Inst); Merck (Inst); MSD (Inst); Nanobiotix (Inst); Novartis (Inst); Syneos Health (Inst)
 
Sadamoto Zenda
Honoraria - Bristol-Myers Squibb Japan; Maruho; Merck; Ono Yakuhin
 
Takeshi Kodaira
Speakers' Bureau - Accuray; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Hitachi; Janssen; Merck Serono; MSD; Ono Pharmaceutical; Reason Why Co.
Research Funding - AstraZeneca (Inst); Japan Agency for Medical Research and Development (Inst); MSD (Inst); National Cancer Center Research and Development Funds (Inst)
 
Naomi Kiyota
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Adlai Nortye; Ono Pharmaceutical; Shift Zero
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Ono Pharmaceutical (Inst)
 
Yasushi Fujimoto
No Relationships to Disclose
 
Koichiro Wasano
Consulting or Advisory Role - Kyorin
Research Funding - Kyorin; Rakuten Medical Japan
 
Ryo Takahashi
Speakers' Bureau - Radiotherapy Quality Assurance Organization For Research, Development & Application; Triangle Products; Varian Medical Systems
Research Funding - JSPS KAKENHI
 
Takashi Mizowaki
Speakers' Bureau - Brainlab; Elekta; Hitachi; Janssen; Varian Medical Systems
Research Funding - Brainlab; Hitachi; Varian Medical Systems
 
Akihiro Homma
Honoraria - Bayer; Bristol-Myers Squibb; Demant; Eisai; Kyorin; Lilly; Meiji Seika Kaisha; Merck; Mitsubishi Tanabe Pharma; MSD K.K; Ono Pharmaceutical; Rakuten Medical; Sanofi; Taiho Pharmaceutical
Research Funding - Eisai (Inst); Iwasaki Denshi (Inst); Japan AMED (Inst); Kyorin (Inst); Mitsubishi Tanabe Pharma (Inst); National Cancer Center (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Torii Pharmaceutical (Inst)
 
Keita Sasaki
No Relationships to Disclose
 
Ryunosuke Machida
No Relationships to Disclose
 
Yuta Sekino
No Relationships to Disclose
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; CMIC Co., Ltd.; Kyowa Kirin Co., Ltd.; m3.com